Advanced

Hemophilia and prophylaxis.

Ljung, Rolf LU (2013) In Pediatric Blood & Cancer2004-01-01+01:00 60(Suppl. S1). p.23-26
Abstract
Clinical experience over decades and numerous retrospective and, recently, also prospective studies clearly demonstrate that prophylactic treatment, albeit much more expensive, is superior to on-demand treatment regardless of whether the outcome is number of joint- or life-threatening bleeds or arthropathy optimal prophylactic treatment should be started early (primary prophylaxis) but various opinions exist on the model. The optimal model should be to individualize prophylaxis taking into account the bleeding phenotype and the individual susceptibility to arthropathy and further develop monitoring by global coagulation assays and pharmacokinetic parameters. This review covers proof of concept of primary prophylaxis in children,... (More)
Clinical experience over decades and numerous retrospective and, recently, also prospective studies clearly demonstrate that prophylactic treatment, albeit much more expensive, is superior to on-demand treatment regardless of whether the outcome is number of joint- or life-threatening bleeds or arthropathy optimal prophylactic treatment should be started early (primary prophylaxis) but various opinions exist on the model. The optimal model should be to individualize prophylaxis taking into account the bleeding phenotype and the individual susceptibility to arthropathy and further develop monitoring by global coagulation assays and pharmacokinetic parameters. This review covers proof of concept of primary prophylaxis in children, comparisons between prophylaxis and on demand treatment, and future trends of prophylactic treatment of hemophilia. Pediatr Blood Cancer © 2012 Wiley Periodicals, Inc. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Pediatric Blood & Cancer2004-01-01+01:00
volume
60
issue
Suppl. S1
pages
23 - 26
publisher
John Wiley and Sons Inc.
external identifiers
  • wos:000311166600007
  • pmid:23109472
  • scopus:84869211465
ISSN
1545-5017
DOI
10.1002/pbc.24340
language
English
LU publication?
yes
id
cc2af1a3-5089-4274-984b-553511b42f0b (old id 3160273)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23109472?dopt=Abstract
date added to LUP
2012-11-01 11:58:22
date last changed
2019-02-27 03:53:12
@article{cc2af1a3-5089-4274-984b-553511b42f0b,
  abstract     = {Clinical experience over decades and numerous retrospective and, recently, also prospective studies clearly demonstrate that prophylactic treatment, albeit much more expensive, is superior to on-demand treatment regardless of whether the outcome is number of joint- or life-threatening bleeds or arthropathy optimal prophylactic treatment should be started early (primary prophylaxis) but various opinions exist on the model. The optimal model should be to individualize prophylaxis taking into account the bleeding phenotype and the individual susceptibility to arthropathy and further develop monitoring by global coagulation assays and pharmacokinetic parameters. This review covers proof of concept of primary prophylaxis in children, comparisons between prophylaxis and on demand treatment, and future trends of prophylactic treatment of hemophilia. Pediatr Blood Cancer © 2012 Wiley Periodicals, Inc.},
  author       = {Ljung, Rolf},
  issn         = {1545-5017},
  language     = {eng},
  number       = {Suppl. S1},
  pages        = {23--26},
  publisher    = {John Wiley and Sons Inc.},
  series       = {Pediatric Blood & Cancer2004-01-01+01:00},
  title        = {Hemophilia and prophylaxis.},
  url          = {http://dx.doi.org/10.1002/pbc.24340},
  volume       = {60},
  year         = {2013},
}